Pharmacology
Baricitinib is a small-molecule JAK inhibitor.
Its primary pharmacological activity involves inhibition of JAK1 and JAK2 signaling.
Because JAK enzymes transmit signals from multiple cytokines, their inhibition can influence several inflammatory pathways simultaneously.
Rheumatoid arthritis evidence
Clinical studies have demonstrated that baricitinib can improve measures of rheumatoid arthritis disease activity in appropriately selected patients.
EMA reviewed multiple clinical studies involving approximately 2,500 adults with rheumatoid arthritis and reported greater proportions of patients achieving clinically meaningful improvements compared with placebo and, in one study, adalimumab.
Alopecia areata evidence
Baricitinib has demonstrated efficacy in severe alopecia areata.
The clinical rationale is related to suppression of immune signaling involved in the autoimmune attack on hair follicles.
The FDA approved baricitinib for severe alopecia areata in 2022, and the indication remains in the current U.S. prescribing information.
Atopic dermatitis evidence
European authorization includes moderate-to-severe atopic dermatitis in appropriate systemic-treatment candidates.
EMA reports clinically relevant benefits in patients with atopic dermatitis, including when used alongside topical corticosteroid therapy.
Pharmacokinetics
Baricitinib is orally administered.
Renal function is clinically important because kidney impairment can affect exposure and dosing recommendations.
The current U.S. prescribing information therefore includes specific renal dosing modifications and restrictions.
Clinical monitoring
Clinical monitoring can include:
- CBC
- Liver enzymes
- Lipid profile
- Kidney function
- TB screening
- Infection assessment
- Cardiovascular risk
- Thrombotic risk
- Pregnancy considerations
Resistance and treatment response
Baricitinib does not produce the same response in every patient.
Treatment response depends on:
- Disease type
- Disease severity
- Previous treatment
- Patient characteristics
- Adherence
- Dose
- Kidney function
- Concomitant therapy
Treatment should be reassessed according to the clinical condition.